Litigation
Merck Sharp & Dohme LLC v. Mylan Pharmaceuticals Inc. et al.
judgment; on appeal1:19-cv-00101-IMK
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2019-05-02
Patents at issue (1)
Plaintiffs (1)
Defendants (2)
Summary
Merits action asserting '708 claim 3 for infringement and challenging claims 1, 2, 3, and 19 for validity. After a five-day bench trial, the court found Mylan's ANDA products infringe claim 3 (Doc. 204, Oct. 26, 2022); Mylan appealed.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).